Although we did not measure the plasma norepinephrine levels in the current study, to partly assess the SNS activity, we expect that deletion of SF-1 in the VMH is likely to be associated with decreased norepinephrine levels as shown by the diminished BAT activity and the late-onset obesity. The gene discussed is SF1; the disease is obesity due to melanocortin 4 receptor deficiency.